Blow For Keros’s PAH Candidate As Dreams Of Surpassing Winrevair Fade

The Lexington, MA-based firm lost three quarters of its value after it voluntarily halted dosing in two arms of a Phase II trial of its lead product, cibotercept, on safety concerns. Some observers think the reaction was overblown, however.